Close Menu

cancer panel

As part of the collaboration, B. Braun China founded a subsidiary, called B. Braun Precision Medicine Technology (BBPM), that opened in Shanghai in May.

Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.

Investigators from several centers outlined tumor features, treatment strategies, and clinical trial classifications coming from tumor-germline clinical sequencing programs.

Farsight Genome Systems is touting the rapid scalability of its analytic pipeline as it seeks to make its technology "future-proof" for clinical genomics labs.

Chugai, a member of the Roche Group, has already filed for regulatory approval of FoundationOne CDx with Japan's Ministry of Health, Labor, and Welfare.

The company plans to grow its business based on the FDA approval and preliminary national coverage determination for its FoundationOne CDx test last year. 

For full-year 2017, the company reported $152.9 million in revenues, up 31 percent over 2016.

At the Precision Medicine World Conference, Invitae executives noted that early experience in the genetic screening pilot found more people received positive results than previously expected.

Under the agreement, new companion diagnostics will be included in updates to FoundationOne CDx, which was recently FDA approved.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.